[en] EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC). Cetuximab is a monoclonal antibody designed to interact with EGFR, block its activation, reduce the downstream signaling pathways and induce EGFR internalization. This study aims to investigate the role of the EGFR signaling pathway and EGFR internalization in a cetuximab-resistant cell line and to propose a new therapeutic strategy to optimize treatment of HNSCC. The HNSCC cell line, CAL33 was sensitive to gefitinib but resistant to cetuximab. Cetuximab induces an unexpected EGFR phosphorylation in CAL33 cells similarly to EGF but this EGFR activation does not trigger EGFR internalization/degradation, the process currently implicated in the response to cetuximab. Cetuximab inhibits ERK and AKT phosphorylation in cetuximab-sensitive A431 cells, whereas the level of AKT phosphorylation is unmodified in cetuximab-resistant cells. Interestingly, CAL33 cells harbor a PIK3CA mutation. The treatment of CAL33 cells with PI3K inhibitor and cetuximab restores the inhibition of AKT phosphorylation and induces growth inhibition. Our results indicate that EGFR internalization is impaired by cetuximab treatment in CAL33 cells and that the AKT pathway is a central element in cetuximab resistance. The combination of cetuximab with a PI3K inhibitor could be a good therapeutic option in PIK3CA-mutated HNSCC.
Mendelsohn J and Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565, 2000.
Kalyankrishna S and Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-2672, 2006.
Ciardiello F and Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39: 1348-1354, 2003.
Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
Rebucci M: Signaling and tumoral develoment. Oncologie 11: 117-122, 2009.
Harari PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11: 689-708, 2004.
Imai K and Takaoka A: Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714-727, 2006.
Baselga J: The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 37 (Suppl 4): S16-S22, 2001.
Vincenzi B, Schiavon G, Silletta M, Santini D and Tonini G: The biological properties of cetuximab. Crit Rev Oncol Hematol 68: 93-106, 2008.
Arnoletti JP, Buchsbaum DJ, Huang ZQ, Hawkins AE, Khazaeli MB, Kraus MH and Vickers SM: Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J Gastrointest Surg 8: 960-969, 2004.
Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006.
Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D and Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987, 2003.
Vermorken JB, Trigo J, Hitt R, et al: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171-2177, 2007.
Chen LF, Cohen EE and Grandis JR: New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 16: 2489-2495, 2010.
Ishikawa N, Daigo Y, Takano A, et al: Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 65: 9176-9184, 2005.
She QB, Solit D, Basso A and Moasser MM: Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9: 4340-4346, 2003.
Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005. (Pubitemid 40271173)
Yoshida T, Okamoto I, Okabe T, et al: Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer 122: 1530-1538, 2008.
Vieira AV, Lamaze C and Schmid SL: Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274: 2086-2089, 1996.
Sorkin A and Von ZM: Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 3: 600-614, 2002.
Wang Y, Pennock S, Chen X and Wang Z: Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol Cell Biol 22: 7279-7290, 2002.
Gioanni J, Fischel JL, Lambert JC, et al: Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol 24: 1445-1455, 1988.
Janmaat ML, Kruyt FA, Rodriguez JA and Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316-2326, 2003.
Meira DD, Nobrega I, De Almeida V, et al: Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway. Eur J Cancer 45: 1265-1273, 2009.
Bozec A, Lassalle S, Gugenheim J, Fischel JL, Formento P, Hofman P and Milano G: Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 95: 722-728, 2006.
Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL and Milano G: Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86: 819-827, 2002.
Qiu W, Schonleben F, Li X, et al: PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 12: 1441-1446, 2006.
Ligresti G, Militello L, Steelman LS, et al: PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 8: 1352-1358, 2009.
Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS and Gonzalez MV: Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114: 242-248, 2005.
Krystal GW, Sulanke G and Litz J: Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 1: 913-922, 2002.
Sartore-Bianchi A, Martini M, Molinari F, et al: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851-1857, 2009.
MacKeigan JP, Taxman DJ, Hunter D, Earp HS III, Graves LM and Ting JP: Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 8: 2091-2099, 2002.
Raben D, Helfrich B, Chan DC, et al: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11: 795-805, 2005.
Yamatodani T, Ekblad L, Kjellen E, Johnsson A, Mineta H and Wennerberg J: Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol 135: 395-402, 2009.
Huang SM, Bock JM and Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935-1940, 1999.
Huang S, Armstrong EA, Benavente S, Chinnaiyan P and Harari PM: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64: 5355-5362, 2004.
Moasser MM, Basso A, Averbuch SD and Rosen N: The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188, 2001.
Nyati MK, Morgan MA, Feng FY and Lawrence TS: Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 6: 876-885, 2006.
Mandic R, Rodgarkia-Dara CJ, Zhu L, et al: Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett 580: 4793-4800, 2006.
Normanno N, De Luca A, Maiello MR, et al: The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 207: 420-427, 2006.
Magne N, Fischel JL, Tiffon C, et al: Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br J Cancer 89: 585-592, 2003. (Pubitemid 37026447)
Sunada H, Magun BE, Mendelsohn J and MacLeod CL: Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83: 3825-3829, 1986.
Jaramillo ML, Leon Z, Grothe S, Paul-Roc B, Abulrob A and O'Connor MM: Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 312: 2778-2790, 2006. (Pubitemid 44246936)
Song JY, Lee SW, Hong JP, Chang SE, Choe H and Choi J: Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells. Cancer Lett 283: 135-142, 2009.
Han W, Zhang T, Yu H, Foulke JG and Tang CK: Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther 5: 1361-1368, 2006. (Pubitemid 44772265)
Sorkin A and Goh LK: Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315: 683-696, 2009.
Wheeler DL, Huang S, Kruser TJ, et al: Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27: 3944-3956, 2008.
Burke P, Schooler K and Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 12: 1897-1910, 2001.
Haugh JM, Schooler K, Wells A, Wiley HS and Lauffenburger DA: Effect of epidermal growth factor receptor internalization on regulation of the phospholipase C-gamma1 signaling pathway. J Biol Chem 274: 8958-8965, 1999.
Haugh JM, Huang AC, Wiley HS, Wells A and Lauffenburger DA: Internalized epidermal growth factor receptors participate in the activation of p21(ras) in fibroblasts. J Biol Chem 274: 34350-34360, 1999.
Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573, 2005.
Jhawer M, Goel S, Wilson AJ, et al: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961, 2008.
Kim SM, Kim JS, Kim JH, et al: Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett 296: 150-159, 2010.
Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092, 2002.
Samuels Y and Velculescu VE: Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3: 1221-1224, 2004.